Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 11, 2015, Pages 2540-2548

  Squitieri, Ferdinando ^a   Di Pardo, Alba ^a   Favellato, Mariagrazia ^a   Amico, Enrico ^a   Maglione, Vittorio ^a   Frati, Luigi ^a  

^a IRCCS NEUROMED   (Italy)

Author keywords

BDNF; Huntington disease; Neuroprotection; Pridopidine; Sig 1R

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; PHOSPHOPROTEIN DARPP 32; PRIDOPIDINE; SIGMA 1 OPIATE RECEPTOR; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE; PPP1R1B PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG MECHANISM; HUNTINGTON CHOREA; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HUNTINGTON DISEASE; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; TRANSFORMED CELL LINE;

ANIMALS; APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; HUNTINGTON DISEASE; MICE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PIPERIDINES;

EID: 84945449223     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12604     Document Type: Article

References (39)

1. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotid repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993; 72: 971-83.
2. André VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther. 2010; 3: 163-78.
3. Chen JY, Wang EA, Cepeda C, et al. Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility. Front Neurosci. 2013; 4: 114.
4. Bird ED. Chemical pathology of Huntington's disease. Annu Rev Pharmacol Toxicol. 1980; 20: 533-51.
5. Spokes EG. Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue. Brain. 1980; 1: 179-210.
6. Ponten H, Kullingsjö J, Lagerkvist S, et al. In vivo pharmacology of the dopaminergic stabilizer pridopidine. Eur J Pharmacol. 2010; 1-3: 88-95.
7. Tedroff J, Sonesson C, Waters N, et al. A pilot study of the novel dopamine stabilizer ACR16 in advanced Parkinson's disease. Mov Disord. 2004; 19: S201.
8. Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci. 2006; 8: 137-42.
9. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2011; 12: 1049-57.
10. Squitieri F, Landwehrmeyer B, Reilmann R, et al. One-year safety and tolerability profile of pridopidine in patients with Huntington disease. Neurology. 2013; 12: 1086-94.
11. Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord. 2013; 10: 1407-15.
12. Ruiz C, Casarejos MJ, Rubio I, et al. The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins. Brain Res. 2012; 1459: 100-12.
13. Natesan S, Svensson KA, Reckless GE, et al. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther. 2006; 2: 810-8.
14. Tadori Y, Kitagawa H, Forbes RA, et al. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol. 2007; 2-3: 103-11.
15. Nilsson M, Carlsson A, Markinhuhta KR, et al. The dopaminergic stabiliserACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 4: 677-85.
16. Sahlholm K, Århem P, Fuxe K, et al. The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the σ-1 receptor. Mol Psychiatry. 2013; 1: 12-4.
17. Hellewell SB, Bruce A, Feinstein G, et al. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinitylabeling. Eur J Pharmacol. 1994; 1: 9-18.
18. Novakova M, Ela C, Barg J, et al. Inotropic action of sigma receptor ligands in isolated cardiac myocytes from adult rats. Eur J Pharmacol. 1995; 1: 19-30.
19. Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2 + ) signaling and cell survival. Cell. 2007; 3: 596-610.
20. Hayashi T, Tsai SY, Mori T, et al. Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders. Expert Opin Ther Targets. 2011; 5: 557-77.
21. Hyrskyluoto A, Pulli I, Törnqvist K, et al. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway. Cell Death Dis. 2013; 23: e646.
22. Di Pardo A, Maglione V, Alpaugh M, et al. Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behaviourbehavioural in Huntington disease mice. Proc Natl Acad Sci USA. 2012; 9: 3528-33.
23. Metz GA, Whishaw IQ. Cortical and subcortical lesions impair skilled walking in the ladder rung walking test: a new task to evaluate fore- and hindlimb stepping, placing, and co-ordination. J Neurosci Methods. 2002; 115: 169-79.
24. Li H, Li SH, Yu ZX, et al. Huntingtin aggregateassociated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci. 2001; 21: 8473-81.
25. Di Pardo A, Amico E, Favellato M, et al. FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Hum Mol Genet. 2014; 23: 2251-65.
26. Maglione V, Marchi P, Di Pardo A, et al. Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1. J Neurosci. 2010; 11: 4072-80.
27. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011; 1: 182-217.
28. Mochel F, Durant B, Durr A, et al. Altered dopamine and serotonin metabolism in motorically asymptomatic R6/2 mice. PLoS ONE. 2011; 3: e18336.
29. Crook ZR, Housman DE. Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice. Proc Natl Acad Sci USA. 2012; 19: 7487-92.
30. Huot P, Lévesque M, Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain. 2007; 130: 222-32.
31. Jahanshahi A, Vlamings R, van Roon-Mom WM, et al. Changes in brainstem serotonergic and dopaminergic cell populations in experimental and clinical Huntington's disease. Neuroscience. 2013; 238: 71-81.
32. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012; 6: 597-603.
33. Reilmann R. Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. Mov Disord. 2013; 8: 1030-3.
34. Waters S, Tedroff J, Kieburtz K. Validation of the Modified Motor Score (mMS): a subscale of the Unified Huntington's Disease Rating Scale (UHDRS) motor score. Neurotherapeutics. 2010; 7: 144.
35. Lundin A, Dietrichs E, Haghighi S, et al. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010; 5: 260-4.
36. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors. 2004; 22: 123-31.
37. Reis HJ, Rosa DV, Guimarães MM, et al. Is DARPP-32 a potential therapeutic target? Expert Opin Ther Targets. 2007; 12: 1649-61.
38. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol. 2007; 81: 294-330.
39. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature. 2003; 421: 373-9.